Buprenorphine: Practical Clinical Guidance for Prescribers

Optimizing Care for Chronic Pain and Opioid Use Disorder (OUD)

Why Buprenorphine?

Buprenorphine is a high-affinity partial mu-opioid receptor agonist with a ceiling effect on respiratory depression and superior safety compared to traditional full agonist opioids. It offers evidence-based efficacy for both chronic pain and OUD. With expanded prescribing access (no longer requiring the DATA X-waiver), buprenorphine is now a vital option in primary and specialty care settings.

Clinical Advantages

- Effective Analgesia: Comparable or superior to morphine, oxycodone, and hydrocodone.
- Safety Profile: Reduced risk of overdose; ceiling effect for respiratory depression.
- Additional Benefits: Reduces opioid-induced hyperalgesia, anxiety, and depression.
- Multimodal Action: Partial mu-agonist, kappa/delta antagonist - supports pain relief and mood stabilization.

Indications & Use

Chronic Pain (with or without OUD): Buprenorphine is endorsed by DHHS, VA/DoD guidelines as a first-line alternative to Schedule II opioids.

Opioid Use Disorder (OUD) Treatment: Proven to reduce all-cause mortality by 50%. Appropriate for both induction and maintenance therapy.

Initiation Strategies

1. Opioid-Naive or Low-Dose Patients

Direct initiation with low-dose buprenorphine (e.g., 0.5 mg BID). Titrate gradually based on analgesic response and tolerability.

2. Opioid-Tolerant Patients

Option A: Taper First, Then Initiate

Gradual weaning off full agonist opioids. Initiate buprenorphine once daily opioid dose is low.

Option B: Concurrent Initiation

Start buprenorphine 0.5–1 mg BID while continuing full agonist. Taper full agonist as buprenorphine is up-titrated.

Example: Transitioning from Oxycodone ER 30 mg BID + IR 5 mg QID

Day	Buprenorphine Dose	Oxycodone Plan
Day 1	0.5 mg BID	Stop PRN oxycodone IR

Day 2	1 mg BID	Continue oxycodone ER BID
Day 3	2 mg BID	Continue ER
Day 4	3 mg BID	Reduce oxycodone ER to PM only
Day 5	4 mg BID	
Day 6	6 mg BID	Discontinue all oxycodone
Day 7	Adjust as needed	

Individualization of microdose initiation regimens is common based on prior dosing and patient tolerability

Acute Pain & Perioperative Considerations

- Continue baseline buprenorphine (split dose q6-8h if needed).
- Supplement with full agonists (short-acting opioids) for breakthrough pain.
- Prioritize multimodal analgesia (NSAIDs, acetaminophen, regional blocks).
- Coordinate care with outpatient MOUD/pain providers.

Prescribing Essentials

No X-waiver required (2023 policy change).

DEA-registered providers can prescribe for pain or OUD.

Formulations include:

- Sublingual (Suboxone, Subutex, Zubsolv)
- Buccal film (Belbuca)
- Transdermal (Butrans)
- Injectable (Sublocade, Brixadi)

Cautions & Monitoring

- Dental injury risk (especially with SL/buccal forms)
- Liver enzyme monitoring recommended
- Avoid concurrent sedatives (e.g., benzodiazepines, alcohol)
- Use naloxone for overdose reversal (may require higher doses)

Final Takeaway

Buprenorphine is a flexible, effective, and safer opioid option for managing chronic pain and OUD. With proper patient selection and initiation strategies, it enables prescribers to improve function, reduce risk, and support recovery.

Additional Helpful Resources:

- https://www.cdc.gov/overdose-resources/pdf/Conversation-Starter_Naloxone_Clinician_508.pdf
- https://www.samhsa.gov/sites/default/files/quick-start-pocket.pdf

Works Cited

Centers for Disease Control and Prevention, "CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022." 3 November 2022. https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm.

Covington, Edward C., et al. "Ensuring Patient Protections When Tapering Opioids: Consensus Panel Recommendations" Mayo Clinic Proceedings, vol 95, Issue 10, 2020. p 2155 – 2171. https://www.mayoclinicproceedings.org/article/S0025-6196(20)30395-5/fulltext

Pain Management Education at UCSF – "Buprenorphine" https://pain.ucsf.edu/opioid-analgesics/buprenorphine

Internet Book of Critical Care (IBCC) – "Buprenorphine & opioid use disorder" (Josh Farkas, 2021). https://emcrit.org/ibcc/buprenorphine/

Psychiatric Research Institute -What is Buprenorphine? https://psychiatry.uams.edu/clinical-care/outpatient-care/cast/buprenorphine/

Buprenorphine: How It's Used to Treat Opioid Use Disorder. https://www.healthline.com/health/drugs/buprenorphine-for-oud

"Conversion from High Dose Full Opioid Agonists to Sublingual Buprenorphine Reduces Pain Scores and Improve Quality of Life for Chronic Pain Patients." Pain Medicine 2014 Vol 15 pp. 2087-2094. https://pubmed.ncbi.nlm.nih.gov/25220043/

Neale et al. "Top ten tips palliative care clinicians should know about buprenorphine"

Journal of Palliative Medicine. 2023; 26(1)DOI: 10.1089/jpm.2022.0399. https://pubmed.ncbi.nlm.nih.gov/36067137/

Van Dorp E., et al, "Naloxone reversal of buprenorphine-induced respiratory depression." Anesthesiology. 2006; 105: 51–57. https://pubmed.ncbi.nlm.nih.gov/16809994/